Healthcare >> CEO Interviews >> March 29, 1999
PHILIP GOULD left Hull University in1978 with a Ph.D. in chemical kinetics
and went to work in physical sciences in the Pharmaceutical Division of
Reckitt and Colman. In 1980, he joined Pfizer central Research in Sandwich,
U.K. to work in pharmaceutical development as a principal research scientist.
In 1985 he then joined American Cynamid Medical Research Division in the U.K.
as Senior Manager in Pharmaceutical Development, leaving in 1988 to join
Glaxo (now GlaxoWellcome) initially as Head of the Pharmaceutical Development
and more recently as head of New Product Introduction and Product
Technology for GW U.K. In early 1998, he took up the role of executive
director of R&D for Cortecs International, an emerging mid-size
Biopharmaceutical company. In December of the same year, Dr. Gould was
appointed acting Chief Executive Officer of Cortecs Plc, this position being
confirmed on January 28, 1999. He is the author of approximately 50
publications, is the holder of a number of patents on novel drug delivery
systems and is also an Honorary Professor of Health Sciences. Profile
Dr. Gould: Cortecs was founded as a biopharmaceutical company in Australia.
It began to look abroad with the intention of buying a company
